Dermira (NASDAQ:DERM) will be releasing its earnings data after the market closes on Wednesday, August 7th. Analysts expect Dermira to post earnings of ($0.90) per share for the quarter.
Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to the consensus estimate of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. On average, analysts expect Dermira to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
DERM traded down $0.40 on Monday, reaching $7.50. The company had a trading volume of 190,434 shares, compared to its average volume of 567,264. The firm has a fifty day moving average of $8.98. The stock has a market cap of $423.98 million, a P/E ratio of -1.43 and a beta of 1.33. The company has a debt-to-equity ratio of 4.36, a current ratio of 7.13 and a quick ratio of 6.92. Dermira has a one year low of $6.00 and a one year high of $15.48.
A number of brokerages recently issued reports on DERM. Mizuho upgraded shares of Dermira from a “neutral” rating to a “buy” rating and decreased their target price for the company from $17.00 to $14.00 in a research report on Thursday, June 6th. Zacks Investment Research lowered shares of Dermira from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating on shares of Dermira in a research report on Wednesday, May 8th. Cantor Fitzgerald reiterated a “buy” rating and issued a $25.00 target price on shares of Dermira in a research report on Friday, May 3rd. Finally, BidaskClub lowered shares of Dermira from a “hold” rating to a “sell” rating in a research report on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.97.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Story: Balance Sheet
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.